Abstract

Acute, rapid, and severe bone loss (ARSBL) and a high fracture rate exceed postmenopausal and age related osteoporosis in many bone illnesses. Drug induced systemic disorders, weakness, immobility, and the sickness dominate these situations. Examples include GIOP, post-transplantation bone disease, stroke, and acute spinal cord injury immobility. These disorders cause 8% spinal bone loss and 5% hip bone loss annually. Effective management can reverse bone loss. This review covers quick and severe bone loss causes.

• 1.   Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 1999;14:1061–6.
• 2.   Cooper MS, Hewison M, Stewart PM. Glucocorticoid activity, inactivity and the osteoblast. J Endocrinol. 1999;163:159–64.
• 3.   Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989;4:137–41.
• 4.   Libanati CR, Baylink DJ. Prevention and treatment of glucocorticoid-induced osteoporosis: a pathogenetic perspective. Chest. 1992;102:1426–35.
• 5.   Reid IR. Glucocorticoid-induced osteoporosis: assessment and treatment. J Clin Densitom. 1998;1:65–73.
• 6.   Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab. 2001;86:5681–5.
• 7.   Nishimura J, Ikuyama S. Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab. 2000;18:350–2.
• 8.   Thiebaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest. 1996;26:549–55.
• 9.   Rich GM, Mudge GH, Laffel GL, LeBoff MS. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant. 1992;11:950–8.
• 10.   Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988;123:2571–7.
• 11.   Awumey EM, Moonga BS, Sodam BR, Koval AP, Adebanjo OA, Kumegawa M, et al. Molecular and functional evidence for calcineurin-A alpha and beta isoforms in the osteoclast: novel insights into cyclosporin A action on bone resorption. Biochem Biophys Res Commun. 1999;254:248–52.
• 12.   Glendenning P, Kent GN, Adler BD, Matz L, Watson I, O’Driscoll GJ, et al. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Clin Endocrinol (Oxf). 1999;50:347–55.
• 13.   Hetzer R, Albert W, Hummel M, Pasic M, Loebe M, Warnecke H, et al. Status of patients presently living 9 to 13 years after orthotopic heart transplantation. Ann Thorac Surg. 1997;64:1661–8.
• 14.   Guo CY, Johnson A, Locke TJ, Eastell R. Mechanisms of bone loss after cardiac transplantation. Bone. 1998;22:267–71.
• 15.   Rich GM, Mudge GH, Laffel GL, LeBoff MS. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant. 1992;11:950–8. [Duplicate of Reference 9]
• 16.   Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab. 1996;81:1740–6.
• 17.   Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001;357:342–7.
• 18.   Feller RB, McDonald JA, Sherbon KJ, McCaughan GW. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl. 1999;5:407–13.
• 19.   Giannini S, Nobile M, Ciuffreda M, Iemmolo RM, Dalle Carbonare L, Minicuci N, et al. Long-term persistence of low bone density in orthotopic liver transplantation. Osteoporos Int. 2000;11:417–24.
• 20.   Ferrari SL, Nicod LP, Hamacher J, Spiliopoulos A, Slosman DO, Rochat T, et al. Osteoporosis in patients undergoing lung transplantation. Eur Respir J. 1996;9:2378–82.
• 21.   Castaneda S, Carmona L, Carvajal I, Arranz R, Diaz A, Garcia-Vadillo A. Reduction of bone mass in women after bone marrow transplantation. Calcif Tissue Int. 1997;60:343–7.
• 22.   Li XJ, Jee WS, Chow SY, Woodbury DM. Adaptation of cancellous bone to aging and immobilization in the rat: a single photon absorptiometry and histomorphometry study. Anat Rec. 1990;227:12–24.
• 23.   Jorgensen L, Jacobsen BK. Changes in muscle mass, fat mass, and bone mineral content in the legs after stroke: a 1 year prospective study. Bone. 2001;28:655–9.
• 24.   Ramnemark A, Nyberg L, Borssen B, Olsson T, Gustafson Y. Fractures after stroke. Osteoporos Int. 1998;8:92–5.
• 25.   Kanis J, Oden A, Johnell O. Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke. 2001;32:702–6.
• 26.   Sato Y, Asoh T, Kondo I, Satoh K. Vitamin D deficiency and risk of hip fractures among disabled elderly stroke patients. Stroke. 2001;32:1673–7.
• 27.   Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med. 2003;163:789–94.
• 28.   Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int. 2001;12:385–90.
• 29.   Castelo-Branco C, Rovira M, Pons F, Duran M, Sierra J, Vives A, et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas. 1996;23:307–12.
• 30.   Rubin M, Bilezikian J. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab. 2002;87:4033–41.

Data Sharing Statement

Funding